345 related articles for article (PubMed ID: 27815868)
1. A Prospective Population Pharmacokinetic Study on Morphine Metabolism in Cancer Patients.
Oosten AW; Abrantes JA; Jönsson S; Matic M; van Schaik RHN; de Bruijn P; van der Rijt CCD; Mathijssen RHJ
Clin Pharmacokinet; 2017 Jul; 56(7):733-746. PubMed ID: 27815868
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetics of morphine and its glucuronides following intravenous administration of morphine in patients undergoing continuous ambulatory peritoneal dialysis.
Pauli-Magnus C; Hofmann U; Mikus G; Kuhlmann U; Mettang T
Nephrol Dial Transplant; 1999 Apr; 14(4):903-9. PubMed ID: 10328468
[TBL] [Abstract][Full Text] [Related]
3. Morphine glucuronide-to-morphine plasma ratios are unaffected by the UGT2B7 H268Y and UGT1A1*28 polymorphisms in cancer patients on chronic morphine therapy.
Holthe M; Klepstad P; Zahlsen K; Borchgrevink PC; Hagen L; Dale O; Kaasa S; Krokan HE; Skorpen F
Eur J Clin Pharmacol; 2002 Aug; 58(5):353-6. PubMed ID: 12185559
[TBL] [Abstract][Full Text] [Related]
4. Influences on serum concentrations of morphine, M6G and M3G during routine clinical drug monitoring: a prospective survey in 300 adult cancer patients.
Klepstad P; Dale O; Kaasa S; Zahlsen K; Aamo T; Fayers P; Borchgrevink PC
Acta Anaesthesiol Scand; 2003 Jul; 47(6):725-31. PubMed ID: 12803591
[TBL] [Abstract][Full Text] [Related]
5. A Compartmental Analysis for Morphine and Its Metabolites in Young Children After a Single Oral Dose.
Velez de Mendizabal N; Jimenez-Mendez R; Cooke E; Montgomery CJ; Dawes J; Rieder MJ; Aleksa K; Koren G; Jacobo-Cabral CO; Gonzalez-Ramirez R; Castañeda-Hernandez G; Carleton BC
Clin Pharmacokinet; 2015 Oct; 54(10):1083-90. PubMed ID: 25773480
[TBL] [Abstract][Full Text] [Related]
6. Concentrations of morphine and morphine metabolites in CSF and plasma during continuous subcutaneous morphine administration in cancer pain patients.
Wolff T; Samuelsson H; Hedner T
Pain; 1996 Dec; 68(2-3):209-16. PubMed ID: 9121807
[TBL] [Abstract][Full Text] [Related]
7. The influence of the route of administration: a comparative study at steady state of oral sustained release morphine and morphine sulfate suppositories.
Du X; Skopp G; Aderjan R
Ther Drug Monit; 1999 Apr; 21(2):208-14. PubMed ID: 10217341
[TBL] [Abstract][Full Text] [Related]
8. Plasma concentrations of morphine, morphine-6-glucuronide and morphine-3-glucuronide and their relationship with analgesia and side effects in patients with cancer-related pain.
Quigley C; Joel S; Patel N; Baksh A; Slevin M
Palliat Med; 2003 Mar; 17(2):185-90. PubMed ID: 12701850
[TBL] [Abstract][Full Text] [Related]
9. Developmental pharmacokinetics of morphine and its metabolites in neonates, infants and young children.
Bouwmeester NJ; Anderson BJ; Tibboel D; Holford NH
Br J Anaesth; 2004 Feb; 92(2):208-17. PubMed ID: 14722170
[TBL] [Abstract][Full Text] [Related]
10. Clinical pharmacokinetics of morphine and its metabolites during morphine dose titration for chronic cancer pain.
De Gregori S; Minella CE; De Gregori M; Tinelli C; Ranzani GN; Govoni S; Allegri M; Regazzi M
Ther Drug Monit; 2014 Jun; 36(3):335-44. PubMed ID: 24595069
[TBL] [Abstract][Full Text] [Related]
11. Oral morphine in cancer pain: influences on morphine and metabolite concentration.
McQuay HJ; Carroll D; Faura CC; Gavaghan DJ; Hand CW; Moore RA
Clin Pharmacol Ther; 1990 Sep; 48(3):236-44. PubMed ID: 2401122
[TBL] [Abstract][Full Text] [Related]
12. Pharmacokinetic modelling of morphine, morphine-3-glucuronide and morphine-6-glucuronide in plasma and cerebrospinal fluid of neurosurgical patients after short-term infusion of morphine.
Meineke I; Freudenthaler S; Hofmann U; Schaeffeler E; Mikus G; Schwab M; Prange HW; Gleiter CH; Brockmöller J
Br J Clin Pharmacol; 2002 Dec; 54(6):592-603. PubMed ID: 12492606
[TBL] [Abstract][Full Text] [Related]
13. Clinical efficacy, safety and pharmacokinetics of a newly developed controlled release morphine sulphate suppository in patients with cancer pain.
Moolenaar F; Meijler WJ; Frijlink HW; Visser J; Proost JH
Eur J Clin Pharmacol; 2000 Jun; 56(3):219-23. PubMed ID: 10952476
[TBL] [Abstract][Full Text] [Related]
14. The effect of old age on the disposition and antinociceptive response of morphine and morphine-6 beta-glucuronide in the rat.
Van Crugten JT; Somogyi AA; Nation RL; Reynolds G
Pain; 1997 Jun; 71(2):199-205. PubMed ID: 9211481
[TBL] [Abstract][Full Text] [Related]
15. An observational study examining the effects of a surgically induced inflammatory response on the distribution of morphine and its metabolites into cerebrospinal fluid.
Wang Y; Goralski KB; Roberts DJ; Landry K; Issa ME; Sleno L; Julien LC; Wood J; Hall RI
Can J Anaesth; 2017 Oct; 64(10):1009-1022. PubMed ID: 28710563
[TBL] [Abstract][Full Text] [Related]
16. Pharmacokinetics of Morphine, Morphine-3-Glucuronide and Morphine-6-Glucuronide in Terminally Ill Adult Patients.
Franken LG; Masman AD; de Winter BC; Koch BC; Baar FP; Tibboel D; van Gelder T; Mathot RA
Clin Pharmacokinet; 2016 Jun; 55(6):697-709. PubMed ID: 26715216
[TBL] [Abstract][Full Text] [Related]
17. The pharmacokinetics of morphine and morphine glucuronide metabolites after subcutaneous bolus injection and subcutaneous infusion of morphine.
Stuart-Harris R; Joel SP; McDonald P; Currow D; Slevin ML
Br J Clin Pharmacol; 2000 Mar; 49(3):207-14. PubMed ID: 10718775
[TBL] [Abstract][Full Text] [Related]
18. Routine drug monitoring of serum concentrations of morphine, morphine-3-glucuronide and morphine-6-glucuronide do not predict clinical observations in cancer patients.
Klepstad P; Borchgrevink PC; Dale O; Zahlsen K; Aamo T; Fayers P; Fougner B; Kaasa S
Palliat Med; 2003 Dec; 17(8):679-87. PubMed ID: 14694919
[TBL] [Abstract][Full Text] [Related]
19. Morphine and morphine metabolite concentrations in cerebrospinal fluid and plasma in cancer pain patients after slow-release oral morphine administration.
Wolff T; Samuelsson H; Hedner T
Pain; 1995 Aug; 62(2):147-154. PubMed ID: 8545139
[TBL] [Abstract][Full Text] [Related]
20. Population pharmacokinetics of oral morphine and its glucuronides in children receiving morphine as immediate-release liquid or sustained-release tablets for cancer pain.
Hunt A; Joel S; Dick G; Goldman A
J Pediatr; 1999 Jul; 135(1):47-55. PubMed ID: 10393603
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]